Cardinal Health, Inc.
Business Model Analysis
How Cardinal Health Makes Money
Annual Revenue: $254.2B
Cardinal Health generates revenue primarily through Healthcare Distribution / Medical Distribution, with roughly $254.2B in annual revenue.
Core Growth Engine: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The...
Revenue Model & Pricing
The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.
Core Revenue Streams
Pharmaceutical Distribution - Branded, Generic, and Specialty
~92%Product sales and fees from distributing branded, generic, and specialty drugs, plus services from specialty practice platforms. Fiscal 2026 segment revenue was $234.8 billion (up 15%) and segment profit was $2.8 billion (up 23%), driven by brand and specialty volume and generics program performance.
Medical and Surgical Products Manufacturing and Distribution
~5%Sales of Cardinal Health-brand and national-brand medical, surgical, and laboratory products. Fiscal 2026 GMPD revenue was $12.7 billion and segment profit was $258 million, including a one-time $100 million IEEPA tariff refund benefit. Fiscal 2027 guidance calls for $200-$220 million of segment profit.
Nuclear Pharmacy, at-Home Solutions, and Logistics
~3%Nuclear and Precision Health Solutions (radiopharmaceuticals), at-Home Solutions (direct-to-patient supplies), and OptiFreight Logistics. Together they generated $6.8 billion of fiscal 2026 revenue (up 26%) and $707 million of segment profit (up 37%), the highest margins in the company.
Growth Strategy
Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.
How Cardinal Health Makes Money: FAQ
How does Cardinal Health generate revenue in its pharmaceutical wholesale business?
Cardinal Health generates revenue primarily by purchasing bulk pharmaceuticals directly from drug manufacturers at negotiated wholesale acquisition costs (WAC) and distributing them daily to retail chains, independent pharmacies, hospitals, and mail-order pharmacies with small distribution fee markups.
What is the distribution service fee model with pharmaceutical manufacturers?
Cardinal Health negotiates Fee-for-Service (FFS) distribution agreements with brand drug manufacturers, receiving guaranteed administrative fees (typically 1.5% to 3.0% of product value) for providing inventory warehousing, cold-chain logistics, and order fulfillment services.
How does Cardinal Health monetize generic pharmaceutical distribution?
Cardinal Health sources generic drugs at scale through Red Oak Sourcing (a 50/50 joint venture with CVS Health), capturing higher gross profit margins on generic pharmaceuticals by leveraging collective purchasing volume to negotiate steep manufacturer discounts.
What is Red Oak Sourcing and how does it strengthen Cardinal Health's business model?
Formed in 2014, Red Oak Sourcing is a 50/50 joint venture between Cardinal Health and CVS Health that negotiates generic pharmaceutical supply contracts with drug manufacturers, representing the single largest generic drug purchasing consortium in the United States.
How does the Global Medical Products and Distribution (GMPD) segment make money?
The GMPD segment designs, manufactures, and distributes Cardinal Health-branded medical consumables (gloves, surgical gowns, fluid management systems, needles, compression devices) and distributes third-party medical products to hospitals and surgery centers.
What is Cardinal Health's Specialty Distribution and Services business model?
Cardinal Health distributes complex, high-cost specialty biologics, cell and gene therapies, and oncology medications to specialty clinics, offering pharmaceutical manufacturers clinical trial support, third-party logistics (3PL), and patient access hub services.
How does Cardinal Health monetize its Nuclear Pharmacy network?
Cardinal Health compounds and delivers customized, short-lived unit-dose radioactive diagnostic isotopes (such as Technetium-99m and PET imaging tracers) directly to hospital radiology suites within tight, multi-hour delivery windows.
Why is high asset turnover essential to Cardinal Health's low-margin wholesale model?
Because pharmaceutical wholesaling operates on razor-thin operating margins (typically 1.0% to 1.5%), Cardinal Health relies on rapid inventory turnover (over 10x to 12x annually) and large volume scale to generate substantial operating cash flow and return on invested capital.
How does Cardinal Health make money?
It operates as one of the "Big Three" pharmaceutical distributors, generating massive, high-volume revenue by purchasing drugs directly from manufacturers in bulk and delivering them daily to tens of thousands of pharmacies and hospitals.
Related Monetization Mechanics
Compare revenue streams, unit economics, and business models
Explore Cardinal Health
Core profile pages, founders and related research hubs for this company.